Dainippon Sumitomo’s BBI608 Colorectal Cancer Phase III Trials Halted
This article was originally published in PharmAsia News
Executive Summary
Dainippon Sumitomo has discontinued its colorectal cancer Phase III trials with anticancer drug BBI608, the company announced on May 23.